WuXi AppTec (HKG: 2359, SHA: 603259), a leading China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the commissioning of two new peptide manufacturing plants. One plant is located at its existing facility in Changzhou, and the other is a new site in Taixing. This expansion adds 32,000 liters to the company’s solid-phase peptide synthesis (SPPS) reactor volumes, enhancing its production capabilities.
Operated by WuXi TIDES, the new peptide plants are equipped with state-of-the-art digital operation systems that feature automated solvent delivery. These systems are designed to optimize production consistency, minimize human errors, and reduce production cycle times. WuXi AppTec provides integrated services for oligonucleotides, peptides, and conjugates, covering both active pharmaceutical ingredients (API) and drug product development from the discovery phase through to commercialization.- Flcube.com
